Patent ID: 8715674

Claim:
A method of treating a PRL-3 expressing cancer in an individual suffering or suspected to be suffering from said cancer, the method comprising administering a therapeutically effective amount of an antibody selected from the group consisting of: (a) an antibody which binds to PRL-3 and comprises a heavy chain variable region sequence comprising SEQ ID NO: 10 and a light chain variable region sequence comprising SEQ ID NO: 12; (b) an antibody which binds to PRL-3 and comprises a heavy chain variable region comprising SEQ ID NO: 6 and a light chain variable region sequence comprising SEQ ID NO: 8; and (c) an anti-PRL-3 antibody capable of binding to an epitope HTHKTR (SEQ ID NO: 39) and which is capable of binding to an intracellular PRL-3 polypeptide by being capable of crossing the plasma membrane; or a pharmaceutical composition comprising such an antibody to the individual.